Business OpportunitiesSun Pharma rises 2.3% on nod for generic drug
Sun Pharmaceutical Industries scrip rose Rs 32 or 2.3 per cent to close the day at Rs 1,429.20 on reports of US Food and Drug Administration’s (USFDA’s) nod for a generic drug.
- Taro files lawsuit against Sun in US - Sun, Caraco to file 30 marketing applications for generics - Sun Pharma"s US arm facing more trouble - Sun Pharma settles patent dispute with Astra Zeneca - Sun Pharma uses own plants for US market after after Caraco trouble - Lawsuit filed against Sun Pharma"s US arm
The company is believed to have received final approval to market Caffeine Citrate in injection and oral solution. The stock opened at Rs 1,397 and made an intra-day high of Rs 1,441.70. The stock is trading 11 per cent lower than its 52-week high of Rs 1,600 reached on 19 May, 2009.